Full Breakdown
WellBN Clinic Prescribed Gender Medication to Minors Without Proper Checks
6/12/2026, 4:42:38 AM
The Unchecked Prescriptions
A safety investigation found that the WellBN GP practice in Brighton prescribed puberty-blocking drugs and cross-sex hormones to 78 patients under 18 between February 2023 and December 2025. More than 20 children received medication without a face-to-face appointment, breaching standard NHS prescribing protocols.
Why the Clinic Was Created
WellBN opened a transgender health hub in 2020 to alleviate long waiting times for the three specialist gender services in England. By 2024 the clinic had registered around 2,000 patients of all ages, many traveling from outside Brighton, reflecting demand for faster access.
Scale of the Issue
The final report detailed that 44 children aged 16 or younger were given puberty blockers, including 12 under 13 and one aged 11. Fifty-one children aged 16 or younger, four of them under 13, received cross-sex hormones. Fifty-three of the 78 cases also presented possible neuro-developmental conditions such as autism or ADHD.
Official Responses
NHS England instructed WellBN to cease new prescriptions for minors and referred several current and former clinicians to medical regulators. One unnamed doctor was suspended from NHS duties pending further inquiry. Dr Christopher Tibbs, regional medical director for NHS England, warned that the clinic delivered specialist care without appropriate qualifications or commissioning. Dr Charlotte Canniff, joint chief medical officer for Surrey and Sussex ICB, noted that most young patients have now been referred to specialist NHS gender services. WellBN’s website reaffirmed its commitment to “safe, high-quality care” and to cooperate with regulators.
Parents and Advocates Speak Out
Families described the prescribing as a “medical scandal” and reported severe stress, with some parents describing suicidal feelings. Rachel Cashman, co-founder of PSHE Brighton, said the situation “ruptured” families and produced collateral damage beyond medical effects. Parents also said they faced an “impossible choice” between consenting to treatment or confronting suspicion and ostracism.
Verbatim Quotes
- “Under no circumstances should this have happened,” — Dr Christopher Tibbs, Regional Medical Director, NHS England
- “It's not just the medical damage, but the collateral damage for relationships and families that is far greater than people have ever really thought to examine,” — Rachel Cashman, Co-founder, PSHE Brighton
- “He felt families were given an "impossible choice" – either sign up for medical treatment or face "suspicion and ostracism just for asking to slow things down".” — Parent (anonymised)
- “We are committed to working closely with NHS partners and regulators to address any recommendations identified within the report and to continue strengthening the services we provide,” — WellBN, website statement
Conflicting Reports & Gaps
The investigation described the 78 cases as “potentially harmed” but did not quantify actual clinical outcomes. Ongoing regulatory reviews may reveal additional affected patients, and the long-term impact on those with neuro-developmental conditions remains unassessed.
What’s Next
Following a 2024 review by Dr Hilary Cass, the UK banned new puberty-blocker prescriptions for gender-questioning children outside clinical trials and tightened cross-sex hormone rules to require specialist sign-off for those around age 16. In March 2026, England paused all new prescriptions for 16- and 17-year-olds pending a public consultation. Further action against individual clinicians is anticipated as regulators complete their inquiries.
